Breast Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

A011401 Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

A011502 Aspirin as adjuvant therapy node-positive, HER2 – Br. Ca. The ABC Trial

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer cannot be removed by an operation has spread to other parts of the body.

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Bane

Study Contact Information

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Bane
  • Other Physicians who can consent: Sheth, Yanes

Study Contact Information

EA1131 Post–op platinum based Chemo vs. Capcitabine, Pts l w/ residual triple neg basal-like BrCA after neoadj. chemo

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

NRG-CC004 Double Blind Dose Finding Trial of Bupropion Vs Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Study Details

  • Study Site/Tumor Location: Breast Cancer (Post-Menopausal)
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

S1501 Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information

S1703 OS of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Vs Usual Care in Metastatic Hormone Receptor Positive Breast Cancer

Study Details

  • Study Site/Tumor Location: Breast
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information